The Australian firm has partnered with Rheinmetall to develop a variant of the Lynx KF41 for the prime’s LAND 400 Phase 3 bid.
TacMed Australia — a supplier of emergency services training and equipment — has announced it has been selected by Rheinmetall Defence Australia (RDA) to develop a Lynx KF41 Ambulance Variant.
The variant is to be offered in RDA’s tender submission for the Commonwealth government’s $18.1-$27.1 billion LAND 400 Phase 3 program.
The partnership was established following the government’s Australian Industry Capability roadshow in the first half of 2020.
TacMed CEO Jeremy Holder said the firm was selected because of its “unique tactical medical experience” and its ability to provide specialised consulting services.
“This is a significant partnership for TacMed Australia and it aligns with our mission of zero preventable deaths at the point of injury, no matter the environment,” Holder said.
“It cements our position as a leader in the field of critical casualty care in high-threat and complex environments.
“With over half of our company being former serving members of the ADF, TacMed will use its experience on the battlefields of Iraq and Afghanistan to play a role in developing the next generation of Australia’s armoured vehicles to protect and save soldiers’ lives.”
Rheinmetall is expected to deliver three Lynx vehicles to compete in RMA trials conducted in Australia from November 2020.
If successful, Rheinmetall has committed to manufacturing the Lynx fleet in Queensland at its new Military Vehicle Centre of Excellence at Redbank, south west of Brisbane.
[Related: Prime and SME link up for LAND 400 vehicle]